Emerging Immunotherapy Approaches for Treating Prostate Cancer

被引:10
|
作者
Meng, Lingbin [1 ]
Yang, Yuanquan [1 ]
Mortazavi, Amir [1 ]
Zhang, Jingsong [2 ]
机构
[1] Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA
[2] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Genitourinary Oncol, 12902 USF Magnolia Dr, Tampa, FL 33612 USA
关键词
immunotherapy; prostate cancer; immune checkpoint inhibitors; bispecific antibodies; CAR T cells; vaccines; cytokines; immunotherapeutic combinations; CAR-T-CELLS; IMMUNE-CHECKPOINT; DOUBLE-BLIND; PHASE-III; PLUS DOCETAXEL; CLINICAL-TRIAL; SIPULEUCEL-T; TUMOR MICROENVIRONMENT; DNA VACCINE; ANTIGEN;
D O I
10.3390/ijms241814347
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunotherapy has emerged as an important approach for cancer treatment, but its clinical efficacy has been limited in prostate cancer compared to other malignancies. This review summarizes key immunotherapy strategies under evaluation for prostate cancer, including immune checkpoint inhibitors, bispecific T cell-engaging antibodies, chimeric antigen receptor (CAR) T cells, therapeutic vaccines, and cytokines. For each modality, the rationale stemming from preclinical studies is discussed along with outcomes from completed clinical trials and strategies to improve clinical efficacy that are being tested in ongoing clinical trials. Imperative endeavors include biomarker discovery for patient selection, deciphering resistance mechanisms, refining cellular therapies such as CAR T cells, and early-stage intervention were reviewed. These ongoing efforts instill optimism that immunotherapy may eventually deliver significant clinical benefits and expand treatment options for patients with advanced prostate cancer.
引用
收藏
页数:26
相关论文
共 50 条
  • [21] Beyond Sipuleucel-T: Immune Approaches to Treating Prostate Cancer
    Michael L. Cheng
    Lawrence Fong
    Current Treatment Options in Oncology, 2014, 15 : 115 - 126
  • [22] Beyond Sipuleucel-T: Immune Approaches to Treating Prostate Cancer
    Cheng, Michael L.
    Fong, Lawrence
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2014, 15 (01) : 115 - 126
  • [23] New Approaches to Immunotherapy for Metastatic Castration-Resistant Prostate Cancer
    Subudhi, Sumit K.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 283 - 286
  • [24] Treating prostate cancer
    Parker, Chris
    BRITISH MEDICAL JOURNAL, 2012, 345
  • [25] Progress in Oligometastatic Prostate Cancer: Emerging Imaging Innovations and Therapeutic Approaches
    Oka, Ryo
    Utsumi, Takanobu
    Noro, Takahide
    Suzuki, Yuta
    Iijima, Shota
    Sugizaki, Yuka
    Somoto, Takatoshi
    Kato, Seiji
    Endo, Takumi
    Kamiya, Naoto
    Suzuki, Hiroyoshi
    CANCERS, 2024, 16 (03)
  • [26] Immunotherapy of prostate cancer
    Doehn, Christian
    EUROPEAN UROLOGY, 2008, 53 (04) : 681 - 683
  • [27] Immunotherapy for prostate cancer
    Karnes, RJ
    Whelan, CM
    Kwon, ED
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (07) : 807 - 817
  • [28] The immunotherapy of prostate cancer
    Dalgleish, AG
    Perry, MJA
    Eaton, JD
    Hrouda, D
    Todryk, SM
    Kirby, RS
    PROSTATE CANCER AND PROSTATIC DISEASES, 2000, 3 (04) : 303 - 307
  • [29] Immunotherapy for prostate cancer
    Fong, L
    Small, EJ
    SEMINARS IN ONCOLOGY, 2003, 30 (05) : 649 - 658
  • [30] Prostate Cancer Immunotherapy
    Karan, Dev
    Van Veldhuizen, Peter
    CURRENT CANCER THERAPY REVIEWS, 2012, 8 (04) : 237 - 237